Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...
Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...
The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...
This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...
GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...
The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...
Senior Lecturer in the Entrepreneurial Management Unit at Harvard Business School (HBS). In the MBA program, Satish has previously taught The Entrepreneurial Manager, a required first-year MBA course, ...
Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...
An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...
Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...
Governance pressure is intensifying at Novartis, with calls to penalize dealmakers for failed M&A and align executive pay ...
Permanent CDER/CBER appointments reduce near-term organizational churn affecting sponsor planning, but durable review consistency will depend on execution and the pending confirmation of a permanent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results